Lance Bergstrom, MD
Ophthalmology · Fargo, NDNPI 1578509733
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Amgen at 31.8% of the total. Among ophthalmology clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $63.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Alcon$2K
- Microsurgical Technology, Inc.$1K
- Alcon Research LLC$959
- Mallinckrodt Hospital Products Inc.$867
- AbbVie$417
- plus $1K from 19 others
Across 771 payments — averaging $2028.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$961K
- Alcon Research LLC$333K
- Ocular Therapeutix, Inc.$214K
- Bausch Health US, LLC$31K
- Sun Pharmaceutical Industries Inc.$20K
- Mallinckrodt Enterprises LLC$5K
What the payments were for
- Speaking & faculty fees$2,65027%
- Travel & lodging$1,56216%
- Food & beverage$4,26144%
- Education$1932%
- Charitable contribution$1,05011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 14 | $3,091 |
| Alcon | 37 | $2,182 |
| Microsurgical Technology, Inc. | 1 | $1,050 |
| Alcon Research LLC | 1 | $959 |
| Mallinckrodt Hospital Products Inc. | 27 | $867 |
| AbbVie(2 entities) | 23 | $417 |
| Sun Pharmaceutical Industries Inc. | 13 | $194 |
| Biotissue Holdings Inc. | 5 | $147 |
| Ocular Therapeutix, Inc. | 4 | $87 |
| Novartis | 2 | $85 |
| Omeros Corporation | 1 | $71 |
| Astellas Pharma US Inc | 2 | $66 |
| Dompe US, Inc. | 3 | $63 |
| Mallinckrodt Enterprises LLC | 3 | $55 |
| The Cameron-ehlen Group, Inc. | 3 | $55 |
| Rxsight Inc | 1 | $50 |
| Harrow Eye, LLC | 2 | $43 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $41 |
| Oyster Point Pharma, Inc. | 2 | $40 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $38 |
| Apellis Pharmaceuticals, Inc. | 1 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $16 |
| Rayner Intraocular Lenses Limited | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,716 in reported general payments places this provider in the 95th percentile of 41 ophthalmology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 54 | $101,053 |
| RestasisCyclosporine | 26 | $23,511 |
| LumiganBimatoprost | 34 | $16,002 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $9,318 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 46 | $9,268 |
| Latanoprost | 650 | $8,933 |
| TyrvayaVarenicline Tartrate | 14 | $8,815 |
| Prednisolone Acetate | 239 | $8,523 |
| CequaCyclosporine | 13 | $7,534 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $6,279 |
| TafluprostTafluprost/Pf | 32 | $5,864 |
| Alphagan PBrimonidine Tartrate | 16 | $5,811 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $4,120 |
| Timolol Maleate | 267 | $4,071 |
| Cyclosporine | 11 | $3,797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $417 | $54,643101 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $40 | $8,81514 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $194 | $7,53413 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $16 | $6,27911 claims |
| AlconSimbrinza | $2,182 | $4,12020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 ophthalmology providers in North Dakota.
Other ophthalmology in Fargo
- Jennifer OlbumFargo$8K
- Michelle AtchisonFargo$3K
- Anne KeatingFargo$3K
- Craig MasonFargo$3K
- Thomas StrindenFargo$3K
- Steven AndersonFargo$2K
- Michael GriessFargo$461
- David AndersonFargo$400
- Mariaha CobbFargo$310
- David GroszFargo$260
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.